Alchemia banks on 2010
By Dylan Bushell-Embling
Thursday, 02 October, 2008
Thursday, 02 October, 2008
Alchemia [ASX: ACL] has recorded an $11 million loss for the financial year but reports a healthy cash reserve of $15.3 million.
Equity increased from around $87 million to $102 million.
The company expects to go into profit in 2010. Its generic fondaparinux, a copy of GSK’s Arixta, for venous thromboembolism, is scheduled for market launch in the US next year through its partner Dr Reddy’s.
Related News
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
